Context Therapeutics Inc. received a notice from Nasdaq on July 29, 2026, stating its common stock failed to maintain the $1.00 minimum closing bid price for 30 consecutive business days under Listing Rule 5550(a)(2). The company has an initial 180-day compliance period ending January 25, 2027, during which it must restore a closing bid price of at least $1.00 for ten consecutive business days to regain compliance. Failure to meet this requirement may trigger eligibility for a second 180-day period contingent on meeting market value standards and notifying Nasdaq. If the company cannot demonstrate an ability to comply within these periods, its shares will be subject to delisting, though it retains the right to appeal such determination to a Nasdaq Hearings Panel. Context Therapeutics Inc. operates in the biotechnology industry, focusing on developing therapies for rare diseases.

On June 24, 2026, Context Therapeutics Inc. stockholders approved an amendment to the company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000. The company also elected seven directors and ratified CohnReznick LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. Context Therapeutics Inc. is a biotechnology company that develops therapeutics for the treatment of cancer.

Context Therapeutics Inc. announced positive interim efficacy and safety results from its ongoing Phase 1 clinical trial for CTIM-76, an investigational Claudin 6 x CD3 T cell engaging bispecific antibody. The company also updated its corporate presentation and hosted a conference call to discuss the clinical trial data. Context Therapeutics Inc. is a biotechnology company focused on developing investigational therapeutics for cancer.